journal article·2026-06-04Open access

Cholesterol‐Mediated Metabolic‐mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer

Shaojie Liu, Chao Xu, Jun Jiang, Limin He, Yike Zhou, Zhengxuan Li, Yu Li, Keying Zhang, Fa Yang, Tong Lu, Hongtao Song, Hai Zhu, Zhihao Hu, Xiaolong Zhao, Kai Gan, Hongji Li, Bo Yang, Rui Zhang, Weihong Wen, Donghui Han, Weijun Qin

Abstract

ABSTRACT Biophysical microenvironment fuels therapeutic resistance, yet the contribution of matrix stiffness to castration‐resistant prostate cancer (CRPC) remains poorly understood. In this study, we established a metabolic‐mechanotransductive crosstalk wherein cholesterol‐driven stromal reprogramming amplifies CRPC progression. Mechanistically, full androgen deprivation (FAD) induces cholesterol metabolic rewiring in prostate cancer (PCa) cells that orchestrates the CH25H‐dependent phenotype transformation of cancer‐associated fibroblast (CAF) into myofibroblastic CAF (myCAF). In turn, the resulting matrix stiffness induces unfolded protein response (UPR) and potentiates IRE1α kinase activity for Xbp1 splicing, while concurrently activating the integrin αVβ3/FAK/STAT3 axis to transcriptionally replenish Xbp1 substrate in PCa cells. This mechanosensitive adaptation thereby confers PCa with resistance to apoptosis induced by FAD. Consequently, pharmacological disruption of this metabolic‐mechanotransductive axis by targeting cholesterol metabolism or blockade of IRE1α‐XBP1s signaling significantly suppress tumor growth, representing a promising therapeutic strategy for CRPC progression.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer, Lipids, and Metabolism · Ferroptosis and cancer prognosis · Prostate Cancer Treatment and Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China

Department of Health Service Base of Health Service Fourth Military Medical University Xi'an China

Department of Urology Daping Hospital Army Medical University Chongqing China

State Key Laboratory of Cancer Biology Department of Immunology Fourth Military Medical University Xi'an China

School of Life Science and Technology Northwestern Polytechnical University Xi'an China

Funding

National Natural Science Foundation of China

References (46)

Show source-provided references
1. 10.1016/j.eururo.2024.03.02710.1016/j.eururo.2024.03.027 ↗
2. 10.1016/j.eururo.2024.04.01010.1016/j.eururo.2024.04.010 ↗
3. 10.1001/jama.294.2.23810.1001/jama.294.2.238 ↗
4. 10.1038/nrc401610.1038/nrc4016 ↗
5. 10.1038/s41556‐020‐00613‐610.1038/s41556‐020‐00613‐6 ↗
6. 10.1016/j.ccell.2020.06.00510.1016/j.ccell.2020.06.005 ↗
7. Cancer‐associated fibroblast‐secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation10.1172/JCI161913 ↗
8. 10.1016/j.ccell.2023.05.01610.1016/j.ccell.2023.05.016 ↗
9. 10.6004/jnccn.2018.727810.6004/jnccn.2018.7278 ↗
10. Physical traits of cancer
11. 10.1038/s41586‐020‐2612‐210.1038/s41586‐020‐2612‐2 ↗
12. 10.1158/1078‐0432.CCR‐24‐151810.1158/1078‐0432.CCR‐24‐1518 ↗
13. 10.1038/s41467‐021‐24009‐810.1038/s41467‐021‐24009‐8 ↗
14. 10.1158/0008‐5472.CAN‐23‐002510.1158/0008‐5472.CAN‐23‐0025 ↗
15. 10.1016/j.addr.2022.11431910.1016/j.addr.2022.114319 ↗
16. Matrix compliance permits NF‐κB activation to drive therapy resistance in breast cancer10.1084/jem.20191360 ↗
17. 10.1007/s00330‐016‐4534‐910.1007/s00330‐016‐4534‐9 ↗
18. 10.1038/s41568‐024‐00740‐410.1038/s41568‐024‐00740‐4 ↗
19. 10.1038/s41467‐023‐36325‐210.1038/s41467‐023‐36325‐2 ↗
20. 10.1038/s41467‐022‐33780‐110.1038/s41467‐022‐33780‐1 ↗
21. 10.1038/s41467‐021‐27322‐410.1038/s41467‐021‐27322‐4 ↗
22. 10.1186/s12943‐022‐01597‐710.1186/s12943‐022‐01597‐7 ↗
23. 10.1038/s42003‐020‐01476‐110.1038/s42003‐020‐01476‐1 ↗
24. 10.1016/j.eururo.2021.12.03910.1016/j.eururo.2021.12.039 ↗
25. 10.1126/science.abn047810.1126/science.abn0478 ↗
26. 10.1186/s12943‐020‐01264‐910.1186/s12943‐020‐01264‐9 ↗
27. 10.1038/s41586‐023‐06740‐y10.1038/s41586‐023‐06740‐y ↗
28. 10.7150/thno.8949510.7150/thno.89495 ↗
29. The endoplasmic reticulum stress response in prostate cancer10.1038/s41585-022-00649-3 ↗
30. 10.1016/j.immuni.2024.03.02110.1016/j.immuni.2024.03.021 ↗
31. 10.1016/j.xcrm.2026.10271210.1016/j.xcrm.2026.102712 ↗
32. 10.1002/smtd.20250024110.1002/smtd.202500241 ↗
33. 10.1038/s41568‐025‐00836‐510.1038/s41568‐025‐00836‐5 ↗
34. 10.1002/EXP.2024019810.1002/EXP.20240198 ↗
35. PTBP1 Regulates DNMT3B Alternative Splicing by Interacting With RALY to Enhance the Radioresistance of Prostate Cancer10.1002/advs.202405997 ↗
36. 10.1186/s12943‐023‐01744‐810.1186/s12943‐023‐01744‐8 ↗
37. 10.1016/j.cell.2024.04.02310.1016/j.cell.2024.04.023 ↗
38. Static and Dynamic: Evolving Biomaterial Mechanical Properties to Control Cellular Mechanotransduction10.1002/advs.202204594 ↗
39. 10.1530/ERC‐19‐018110.1530/ERC‐19‐0181 ↗
40. 10.1186/s13045‐025‐01688‐010.1186/s13045‐025‐01688‐0 ↗
41. Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer10.1016/j.ccell.2025.06.021 ↗
42. 10.1002/pros.2067410.1002/pros.20674 ↗
43. 10.1038/s43018‐025‐00952‐z10.1038/s43018‐025‐00952‐z ↗
44. 10.1016/j.cell.2014.08.01610.1016/j.cell.2014.08.016 ↗
45. 10.1002/eji.20144477710.1002/eji.201444777 ↗
46. Isolation of normal and cancer‐associated fibroblasts from fresh tissues by Fluorescence Activated Cell Sorting (FACS)